pacificdesignstudios.com

TrialStat CEO Jonathan Barker to Speak at the Clinical Trials Congress in Orlando, Florida February 25

Orlando, FL (PRWEB) February 25, 2008 -- Jonathan Barker, President and CEO of TrialStat, will speak at the Clinical Trials Congress (CTC) in Orlando on February 25 where he will examine the strategic application of software-as-a-service (SaaS) or on demand technologies to simplify the conduct and management of clinical research. He will be available to answer questions from the media following his speech.

CTC, one of the industry?s foremost conferences, brings together executives from the world?s largest pharmaceutical and biotechnology companies for three days to discuss new innovative trends on better managing and optimizing clinical research.

Details of the presentation are as follows:

Who: Jonathan Barker, TrialStat President and CEO

When: Speaking on February 25 at 2:20pm, Track 4

Where: Clinical Trials Congress ? Royal Pacific Resort, Orlando, Florida.

What: Simplifying an Industry

Booth: 511

TrialStat is the industry?s first on demand or SaaS-based electronic data capture (EDC) provider. ClinicalAnalytics 4.0? (CA 4.0), the company?s on demand EDC solution, enhances the ability of biopharma and CRO customers to more effectively manage their studies with sophisticated reporting, easy-to-use post data entry validation and configurable study management functionality though the software?s secure browser interface. CA 4.0 is the first EDC platform to allow all aspects of the study to be configured, deployed and managed through a single browser-based interface, which enables customers to deploy their studies faster than traditional EDC client server software.

For media inquiries, please contact:

Muay Lim

TrialStat Corporation

613-741-9909 ext 153

mlim@trialstat.com

ClinicalAnalytics 4.0 is a trademark of TrialStat Corporation.

###

This press release has been reprinted from PRWEB per the terms and conditions of the copyright notice.
pacificdesignstudios.com



Privacy Policy | Copyright/Trademark Notification